News
ONCSQ
0.0001
NaN%
--
Weekly Report: what happened at ONCSQ last week (1208-1212)?
Weekly Report · 3d ago
Weekly Report: what happened at ONCSQ last week (1201-1205)?
Weekly Report · 12/08 10:43
Weekly Report: what happened at ONCSQ last week (1124-1128)?
Weekly Report · 12/01 10:37
Weekly Report: what happened at ONCSQ last week (1117-1121)?
Weekly Report · 11/24 10:43
Weekly Report: what happened at ONCSQ last week (1110-1114)?
Weekly Report · 11/17 10:44
Weekly Report: what happened at ONCSQ last week (1103-1107)?
Weekly Report · 11/10 10:41
Weekly Report: what happened at ONCSQ last week (1027-1031)?
Weekly Report · 11/03 10:41
Weekly Report: what happened at ONCSQ last week (1020-1024)?
Weekly Report · 10/27 10:45
Weekly Report: what happened at ONCSQ last week (1013-1017)?
Weekly Report · 10/20 10:40
Weekly Report: what happened at ONCSQ last week (1006-1010)?
Weekly Report · 10/13 10:44
Weekly Report: what happened at ONCSQ last week (0929-1003)?
Weekly Report · 10/06 10:40
Weekly Report: what happened at ONCSQ last week (0922-0926)?
Weekly Report · 09/29 10:41
Weekly Report: what happened at ONCSQ last week (0915-0919)?
Weekly Report · 09/22 10:41
Weekly Report: what happened at ONCSQ last week (0908-0912)?
Weekly Report · 09/15 11:34
Weekly Report: what happened at ONCSQ last week (0901-0905)?
Weekly Report · 09/08 11:37
Weekly Report: what happened at ONCSQ last week (0825-0829)?
Weekly Report · 09/01 11:31
Weekly Report: what happened at ONCSQ last week (0818-0822)?
Weekly Report · 08/25 11:44
Weekly Report: what happened at ONCSQ last week (0811-0815)?
Weekly Report · 08/18 11:35
Weekly Report: what happened at ONCSQ last week (0804-0808)?
Weekly Report · 08/11 11:43
Weekly Report: what happened at ONCSQ last week (0728-0801)?
Weekly Report · 08/04 11:46
More
Webull provides a variety of real-time ONCSQ stock news. You can receive the latest news about Oncosec Med Inc through multiple platforms. This information may help you make smarter investment decisions.
About ONCSQ
OncoSec Medical Incorporated is a clinical-stage biotechnology company. The Company is focused on developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate disease. Its lead immunotherapy investigational product candidate-TAVO (tavokinogene telseplasmid)-enables the intratumoral delivery of DNA-based interleukin 12 (IL-12), a naturally occurring protein with immune-stimulating functions. The therapeutic approach TAVO-EP, which employs electroporation, is designed to produce a localized expression of IL-12 in the tumor microenvironment and, thereby, stimulate the immune system to target and attack tumors.